Colorectal Screening and Hormonal Health: What Hormones Have to Do with Colon Cancer Risk
Colorectal cancer is the second leading cause of cancer death in the United States, and yet it is among the most preventable cancers when screened for appropriately. What is less commonly discussed — even in medical settings — is that hormonal health plays a meaningful role in colorectal cancer risk, and that the hormonal changes of menopause may increase a woman's susceptibility to colorectal disease over time.
Why Colonoscopy Matters More Than People Think
A colonoscopy is the gold standard for colorectal cancer screening. Unlike stool-based tests, which can detect blood or abnormal DNA in the stool, a colonoscopy allows a gastroenterologist to directly visualize the entire colon, identify and remove precancerous polyps during the procedure itself, and evaluate any areas of concern in real time. The vast majority of colorectal cancers develop from adenomatous polyps that take years to become malignant — which means colonoscopy, when performed at the right intervals, can prevent cancer from occurring rather than simply detecting it early.
Current guidelines from the American Cancer Society recommend that average-risk adults begin colorectal cancer screening at age 45. People with a personal or family history of colorectal polyps or cancer, inflammatory bowel disease, or certain genetic syndromes should begin earlier and screen more frequently. Discussing your individual risk factors with your physician will determine the appropriate starting age and interval for you.
The Hormonal Dimension of Colorectal Risk
Multiple lines of evidence suggest that estrogen has a protective effect on the colon. Observational studies have consistently shown lower rates of colorectal cancer in premenopausal women compared to age-matched men — a gap that narrows significantly after menopause. This pattern closely mirrors the relationship between estrogen and cardiovascular disease and suggests a direct protective role for estrogen in colonic tissue.
Estrogen receptors — particularly estrogen receptor beta (ER-beta) — are expressed throughout the colon. In normal colonic tissue, ER-beta activation promotes cellular differentiation and inhibits proliferation, which suppresses tumor development. In colorectal cancer tissue, ER-beta expression is often markedly reduced, suggesting that estrogen-receptor signaling normally functions as a tumor suppressor in the colon.
After menopause, when estrogen levels decline substantially, this protective signaling is reduced. The result is a gradual increase in colorectal cancer risk that accumulates over the postmenopausal years — one reason why the incidence of colorectal cancer is highest in older women.
What the Research Says About Hormone Therapy and Colorectal Risk
Several large studies have found associations between hormone therapy use and reduced colorectal cancer risk in women. The Women's Health Initiative (WHI) — the large randomized controlled trial examining combined estrogen-progestin therapy — found a 37 percent reduction in colorectal cancer incidence in the hormone therapy group compared to placebo. This finding was notable because it was not the primary outcome being studied, giving it additional credibility as an incidental finding rather than a hypothesis-driven result.
Estrogen-only therapy in women who have had hysterectomies has also shown protective associations in observational data. While these findings do not make hormone therapy a colorectal cancer prevention strategy per se — the decision to use BHRT involves many other considerations — they add to the picture of estrogen's broad protective effects across multiple body systems.
Other Hormonal and Metabolic Factors Affecting Colon Health
Beyond estrogen, several other hormonal and metabolic factors affect colorectal cancer risk. Insulin resistance and elevated circulating insulin — closely linked to imbalanced cortisol, declining testosterone, and poor metabolic health — are established risk factors for colorectal cancer and adenoma development. Insulin is a potent growth factor for colonic epithelial cells and promotes the progression of polyps to cancer.
Chronic inflammation, often driven by cortisol dysregulation, visceral adiposity, and hormonal imbalance, also contributes to colorectal cancer risk. Inflammatory cytokines promote the same cellular pathways that drive polyp development. A lifestyle and hormonal strategy that reduces chronic inflammation — optimized hormones, regular exercise, anti-inflammatory nutrition, stress management — supports colon health in addition to its many other benefits.
Practical Steps for Colorectal Health
No matter your hormonal status, colonoscopy at the recommended intervals is irreplaceable. Hormone therapy does not substitute for screening — it may complement it. Beyond screening, colorectal health is supported by a high-fiber diet rich in vegetables, legumes, and whole grains; regular physical activity; limiting processed meat; maintaining a healthy weight; avoiding smoking; and moderating alcohol consumption.
If you are postmenopausal and have not had a recent hormone evaluation, and you have not yet addressed your colorectal screening schedule, both are appropriate agenda items for your next medical appointment.
Kenton Bruice, M.D. approaches hormonal health as a cornerstone of long-term disease prevention — including reducing the metabolic and inflammatory risks that contribute to colorectal cancer. To discuss your hormonal health and preventive care strategy, schedule a consultation at his Denver, Aspen, or St. Louis practice.